News
Press Releases
December 4, 2024
QurAlis Doses First Patient With ALS in Phase 1 Clinical Trial Evaluating QRL-101, a First-in-Class Kv7 Precision Therapy for ALS
November 25, 2024
QurAlis to Participate at the Piper Sandler 36th Annual Healthcare Conference
November 19, 2024
QurAlis’ ANQUR Clinical Trial of QRL-201 in ALS Advances to Dose Range-Finding (DRF) Phase With First Participant Dosed
November 12, 2024
QurAlis to Participate at the Stifel 2024 Healthcare Conference
September 19, 2024
QurAlis Announces Expansion of its Selective Kv7.2/7.3 Ion Channel Opener, QRL-101, Into Epilepsy
September 10, 2024
QurAlis Doses First Participant Cohort in Phase 1 Multiple-Ascending Dose (MAD) Clinical Trial Evaluating QRL-101, a First-in-Class Kv7 Precision Therapy for ALS
August 21, 2024
QurAlis to Participate in Upcoming Investor and Industry Conferences in September
June 25, 2024
QurAlis Expands its Industry-Leading Precision Medicine Approach in Splicing Targets Beyond Neurodegeneration Into Fragile X Syndrome (FXS)
June 11, 2024
QurAlis Expands Leadership Team With Doug Williamson, M.D., as Chief Medical Officer and Jason Brown, MBA, as Chief Financial Officer and Appoints Shafique Virani, M.D., to Board of Directors
June 3, 2024
QurAlis Grants Lilly Exclusive Global License for QRL-204, a Potentially First-in-Class Precision Therapy That Restores UNC13A Function in ALS and FTD
March 12, 2024
QurAlis to Present at the Stifel 2024 CNS Days
March 4, 2024
QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
February 5, 2024
QurAlis to Participate in Upcoming Investor Conferences in February
January 3, 2024
QurAlis Strengthens Global Presence With Opening of European Headquarters That Includes R&D Manufacturing
November 29, 2023
QurAlis to Present Data That Show TDP-43 Pathology Drives Loss of Synaptic UNC13A Function in Neurodegenerative Diseases Including ALS and Frontotemporal Dementia
November 20, 2023
QurAlis to Present at the Piper Sandler 35th Annual Healthcare Conference
September 6, 2023
QurAlis to Present Data Showing Link Between TDP-43 Pathology and Role of UNC13A in Neuronal Biology Related to ALS and Other Neurodegenerative Diseases
July 11, 2023
QurAlis Receives Clinical Trial Authorisation (CTA) in the U.K. for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS
June 27, 2023
QurAlis and Unlearn Announce Collaboration to Accelerate and Optimize ALS Clinical Trials With Generative Artificial Intelligence Technologies
June 8, 2023
QurAlis’ FlexASOs Show High Potency and Improved Safety Over Standard ASOs
June 6, 2023
QurAlis Receives Clinical Trial Authorisation (CTA) in European Union (EU) for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS
June 1, 2023
QurAlis to Participate in Upcoming Investor Conferences in June
April 6, 2023
QurAlis Announces First Patient Dosed With QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS
March 20, 2023
QurAlis Reveals Newest Program Targeting UNC13A RNA Mis-splicing Incorporating its FlexASO™ Platform
March 9, 2023
QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases
January 5, 2023
QurAlis Announces First-in-Human Dose in Phase 1 Clinical Trial of QRL-101, a First-in-Class Kv7 Precision Therapy for ALS
December 8, 2022
QurAlis Receives Health Canada Clinical Trial Application Authorization for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS
September 13, 2022
QurAlis to Present at 22nd Annual Biotech in Europe Forum
July 27, 2022
QurAlis to Present at H.C. Wainwright Private Company Showcase
June 21, 2022
QurAlis Announces the Appointment of Anne C. Whitaker as Chair of the Board
May 25, 2022
QurAlis Presents at ALS Drug Development Summit 2022
March 22, 2022
QurAlis to Present at H.C. Wainwright Gene Therapy and Gene Editing Virtual Conference
March 15, 2022
QurAlis Presents Data About STATHMIN-2 Role in Neuronal Disease Biology and TDP-43 Biomarker Identification at AD/PD™ 2022
February 8, 2022
QurAlis Hires Key Regulatory Affairs, Clinical Operations, and Global Supply Chain Management Experts to Support Strategic Objectives
January 3, 2022
QurAlis to Present at H.C. Wainwright BioConnect 2022 Virtual Conference
December 22, 2021
QurAlis Announces Publication in Molecular Biology of the Cell of Next Generation Drug Screening Platform for ALS Developed by Company Founders
December 6, 2021
QurAlis Presents New Data Confirming Role of STATHMIN-2 in Neuronal Disease Biology at 32nd International Symposium on ALS/MND
November 18, 2021
QurAlis to Present at 33rd Annual Piper Sandler Virtual Healthcare Conference
September 14, 2021
QurAlis Announces Development Candidate for ALS Targeting STATHMIN-2
June 8, 2021
Cell Reports Publishes Discovery Data Supporting the Importance of Ion Channel, Kv7.2/7.3 as a Therapeutic Target in ALS
May 26, 2021
QurAlis Boosts World-Class Leadership Team with Addition of Three New Members
February 2, 2021
QurAlis Continues to Expand Leadership Team with Two Key Hires
December 10, 2020
QurAlis’ Selective Kv7 Opener, a Drug Candidate for ALS, Demonstrates up to 20-Fold Increase in Potency and Dramatic Reduction in Side Effects Compared to Retigabine in Preclinical Models
December 2, 2020
QurAlis to Present Data on Two Precision Medicine Programs (Kv7 and TBK1) at MNDA 31st International Symposium on ALS/MND
October 29, 2020
QurAlis Announces Appointment of new Chief Medical Officer and Formation of Clinical Advisory Board
July 1, 2020
QurAlis Announces Agreement to Strengthen ALS Pipeline
May 13, 2020
QurAlis raises $42 Million Series A Financing to Develop New Therapies for Amyotrophic Lateral Sclerosis (ALS)
April 5, 2018
QurAlis Launches with Seed Funding from MPH, Amgen and Alexandria, united in the fight to cure ALS
December 15, 2017
